Semaglutide Cost New Hampshire — 2026 Price Breakdown

Semaglutide Cost New Hampshire — 2026 Price Breakdown

New Hampshire residents paid an average of $1,349 monthly for brand-name Wegovy in 2025 when insurance didn't cover it. But compounded semaglutide from licensed telehealth providers costs 70–80% less at $297–$399 per month including shipping and medical consultation. The price difference isn't about quality or efficacy. Both contain the same active GLP-1 receptor agonist molecule. It's about manufacturing pathway: Novo Nordisk's branded formulation carries FDA approval of the finished drug product, while compounded versions are prepared by FDA-registered 503B pharmacies under USP sterile compounding standards without that final product approval. Our team has worked with hundreds of New Hampshire patients navigating this exact decision across Manchester, Nashua, Concord, and rural areas where local obesity medicine specialists often have 3–6 month waitlists.

What does semaglutide cost in New Hampshire in 2026?

Semaglutide cost in New Hampshire ranges from $297 monthly for compounded telehealth prescriptions to $1,430 for brand-name Wegovy without insurance coverage. The price varies based on whether you use compounded or brand-name medication, your insurance formulary tier, and whether your provider qualifies you for manufacturer savings programs. Most New Hampshire residents without GLP-1 coverage through Anthem BCBS, Harvard Pilgrim, or Cigna pay between $297–$399 monthly through licensed telehealth platforms that ship compounded semaglutide directly.

Here's what drives the semaglutide cost variation in New Hampshire: brand-name Wegovy and Ozempic carry the full FDA approval premium. Manufacturing, clinical trial costs, and patent protection built into every pen. Compounded semaglutide uses the same active molecule but is prepared by state-licensed pharmacies at a fraction of the cost because it bypasses brand infrastructure. This article covers what compounded vs brand-name pricing looks like for New Hampshire patients, which insurance plans cover GLP-1 medications in 2026, and how telehealth platforms like TrimRx have changed access for residents across the state.

Brand-Name vs Compounded Semaglutide Pricing in New Hampshire

Brand-name Wegovy (semaglutide 2.4mg weekly for weight loss) costs $1,349–$1,430 per month at CVS, Walgreens, and Hannaford pharmacies across New Hampshire when purchased without insurance. Ozempic (semaglutide 0.5mg–2mg for type 2 diabetes, prescribed off-label for weight loss) runs $968–$1,025 monthly. These prices reflect Novo Nordisk's manufacturing costs, FDA approval process expenses, and patent exclusivity that expires in 2031–2032. If your insurance plan covers GLP-1 medications. And approximately 45% of New Hampshire employer-sponsored plans did in 2025 according to state Department of Insurance filings. Your copay drops to $25–$50 monthly for brand-name products.

Compounded semaglutide costs $297–$399 monthly through telehealth providers licensed to serve New Hampshire residents. This price includes the medication, medical consultation with a licensed prescriber, and shipping to any New Hampshire address. Compounded versions are prepared as lyophilised powder that patients reconstitute with bacteriostatic water before subcutaneous injection. The active ingredient is pharmaceutical-grade semaglutide acetate sourced from FDA-registered suppliers and compounded by 503B outsourcing facilities that operate under continuous FDA inspection. What you're not paying for: the brand name, the pre-filled pen device, and the final product FDA approval that Wegovy and Ozempic carry.

The pharmacological difference between compounded and brand-name semaglutide is functionally zero. Both bind to GLP-1 receptors in the hypothalamus and gastrointestinal tract with the same mechanism of action. The regulatory difference is significant: brand-name products have FDA approval of the complete drug product (active ingredient + formulation + delivery device), while compounded medications are prepared under Section 503B of the Federal Food, Drug, and Cosmetic Act, which allows compounding during drug shortages or when a prescriber determines medical necessity. The FDA confirmed semaglutide shortage status from March 2022 through December 2024, and compounding pharmacies continue to operate under state and federal oversight even after shortage resolution.

Insurance Coverage for Semaglutide in New Hampshire

Anthem Blue Cross Blue Shield. The largest health insurer in New Hampshire with roughly 240,000 covered lives. Added Wegovy to its formulary in January 2024 for members with documented BMI ≥30 or BMI ≥27 with one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea). Prior authorisation requires proof of 3-month supervised weight loss attempt through dietary modification and at least 150 minutes weekly of structured physical activity. If approved, Anthem members pay a Tier 3 copay of $45–$75 monthly depending on plan type. Harvard Pilgrim Health Care, which merged with Point32Health in 2021, covers Wegovy under similar criteria but restricts coverage to patients who haven't previously discontinued GLP-1 therapy for reasons other than side effects.

Medicare Part D does not cover GLP-1 medications prescribed solely for weight loss under federal statute. The Social Security Act explicitly excludes weight loss drugs from Part D formularies. New Hampshire Medicare beneficiaries can access semaglutide only if prescribed for an FDA-approved diabetes indication (Ozempic) or if they have a Medicare Advantage plan that offers supplemental weight management benefits beyond standard Part D coverage. Approximately 15% of New Hampshire Medicare Advantage plans offered this supplemental benefit in 2025. Medicaid coverage in New Hampshire is more restrictive: the state's Medicaid program (administered through New Hampshire Healthy Families) does not cover Wegovy or any GLP-1 medication for weight loss as of 2026, though it does cover Ozempic for type 2 diabetes management.

Insurance denial is the most common reason New Hampshire residents turn to compounded semaglutide through telehealth providers. When your plan won't cover GLP-1 therapy. Or when prior authorisation is denied despite meeting clinical criteria. The choice becomes paying $1,349 monthly out-of-pocket for brand-name or $297–$399 for compounded. For most patients, that's not really a choice. TrimRx serves New Hampshire residents who fall into this coverage gap: clinically appropriate candidates for GLP-1 therapy whose insurance either doesn't cover weight loss medications or whose prior authorisation was denied.

Semaglutide Cost New Hampshire: Complete Price Comparison

The Novo Nordisk Savings Card reduces Wegovy copays to $25 monthly for commercially insured patients. But it only works if your insurance already covers the medication. If your plan excludes GLP-1 drugs entirely or denies prior authorisation, the savings card doesn't apply. The manufacturer's patient assistance program serves uninsured patients or those whose insurance denies coverage, but eligibility is capped at 400% of federal poverty level ($60,000 annual income for a single-person household in 2026) and requires 6–8 weeks for application processing.

Key Takeaways

• Semaglutide cost in New Hampshire ranges $297–$1,430 monthly depending on whether you use compounded telehealth sources or brand-name retail pharmacy purchases
• Compounded semaglutide contains the same active GLP-1 receptor agonist molecule as Wegovy and Ozempic but costs 70–80% less because it bypasses brand manufacturing and lacks final FDA product approval
• Anthem BCBS and Harvard Pilgrim cover Wegovy for New Hampshire members with BMI ≥30, but prior authorisation requires documented 3-month supervised weight loss attempt first
• Medicare Part D does not cover semaglutide for weight loss under federal statute. Only for diabetes management as Ozempic
• New Hampshire Medicaid does not cover GLP-1 medications for weight loss as of 2026, creating significant access barriers for low-income residents
• TrimRx provides compounded semaglutide to New Hampshire residents at $297–$399 monthly including consultation and shipping when insurance denies coverage

What If: Semaglutide Cost Scenarios in New Hampshire

What if my insurance denied prior authorisation for Wegovy — can I appeal?

Yes, and you should. Request a formal letter of medical necessity from your prescribing physician that documents your BMI, weight-related comorbidities, and prior weight loss attempts. Anthem and Harvard Pilgrim both have two-tier appeal processes: internal review (30-day response window) and external independent review if the internal appeal is denied. Submit clinical trial data showing semaglutide's efficacy for your specific situation. The STEP 1 trial published in NEJM demonstrated 14.9% mean body weight reduction at 68 weeks, significantly exceeding the 5% threshold that defines clinical significance. Appeals succeed roughly 40% of the time when documentation is thorough.

What if I lose my job and my insurance mid-treatment — what happens to my prescription?

If you lose employer-sponsored coverage that was paying for brand-name Wegovy, you have three options: apply for Novo Nordisk's patient assistance program if your income qualifies, transition to compounded semaglutide through a telehealth provider like TrimRx at $297–$399 monthly, or pay the full $1,349 retail price. Most patients choose option two because patient assistance approval takes 4–6 weeks and creates a treatment gap. Compounded semaglutide allows you to continue weekly dosing without interruption while navigating insurance changes.

What if I'm on New Hampshire Medicaid — are there any coverage pathways for semaglutide?

New Hampshire Medicaid does not cover semaglutide for weight loss, but it does cover Ozempic if you have a documented type 2 diabetes diagnosis with HbA1c ≥7.0% despite metformin therapy. If you meet diabetes criteria, your prescriber can write for Ozempic (covered) rather than Wegovy (not covered). The active molecule is identical, and off-label prescribing for weight loss is legal and common. If you don't have diabetes, Medicaid won't cover any GLP-1 therapy, and you'll need to self-pay for compounded semaglutide or seek manufacturer assistance.

The Bottom-Line Truth About Semaglutide Cost in New Hampshire

Here's the honest answer: the $1,349 brand-name price isn't what most New Hampshire residents actually pay. But it's also not as simple as 'just use compounded and save 75%'. If you have commercial insurance that covers GLP-1 medications, brand-name Wegovy with a $25–$50 copay is the better option. You get the FDA-approved formulation, the convenience of a pre-filled pen, and the legal protection of full regulatory approval. If your insurance denies coverage or you're uninsured, compounded semaglutide at $297–$399 is the only financially viable path for most people. The medication works identically because the active molecule is identical. What you're trading is regulatory approval of the final product and device convenience for affordability.

The pricing gap exists because pharmaceutical pricing in the US is divorced from manufacturing cost. Semaglutide's active ingredient costs approximately $5–$8 per weekly dose to produce at scale. The $1,349 brand price reflects R&D recoupment, patent exclusivity, and market positioning. Not ingredient cost. Compounded pharmacies can charge $75–$100 per weekly dose because they're not recouping those upstream expenses. You're not getting an inferior product when you use compounded semaglutide. You're getting the molecule without the brand infrastructure cost.